Cystic Fibrosis-Related Diabetes in Poland
- PMID: 35409752
- PMCID: PMC8998285
- DOI: 10.3390/ijerph19074069
Cystic Fibrosis-Related Diabetes in Poland
Abstract
Cystic fibrosis (CF) is the most common autosomal recessive inherited monogenic disease in Caucasians. As medical technology progresses and the quality of patient care improves, the survival time of patients with CF has increased, which results in more frequent comorbidities such as cystic fibrosis-related diabetes (CFRD). CFRD is the result of abnormal glucose metabolism characterized primarily by insulin deficiency, exacerbated periodically by insulin resistance. The aim of our study was to analyze the epidemiology of patients with CFRD in Poland on the basis of data collected from six CF treatment centers. Analyses were performed on 1157 CF patients who were treated at one of the six CF care centers. CFRD was diagnosed according to standard criteria. All data including demographics, types of CFTR mutations, CFRD duration, and microorganisms in the sputum were obtained from the patients' medical history. Our study indicates that the prevalence of CFRD in Poland is 12.9%. CFRD was most often diagnosed between the ages of 11 and 20 (60% of patients), while 23% of patients were diagnosed between 21 and 30 years of age. Furthermore, we observed that approximately 3-5% of patients under the age of 10 had CFRD. We found out that the type of mutation did not affect the frequency of CFRD development. Factors that increased the risk of developing CFRD include underweight and chronic Pseudomonas aeruginosa infection. Due to the extended lifespan of CF patients, the number of CFRD patients is currently increasing. We believe that the results of our study may complement information from other studies or may be useful in planning health policy in Poland.
Keywords: F508del mutation; cystic fibrosis-related diabetes; diabetes; prevalence.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
The course of glucose intolerance in children with cystic fibrosis: a retrospective study - preliminary report.Dev Period Med. 2015 Jan-Mar;19(1):80-91. Dev Period Med. 2015. PMID: 26003073
-
New Concepts in the Pathogenesis of Cystic Fibrosis-Related Diabetes.J Clin Endocrinol Metab. 2022 May 17;107(6):1503-1509. doi: 10.1210/clinem/dgac020. J Clin Endocrinol Metab. 2022. PMID: 35106591 Review.
-
Cystic fibrosis related diabetes mellitus - diagnostic and management challenges.Curr Diabetes Rev. 2010 Jan;6(1):9-16. doi: 10.2174/157339910790442600. Curr Diabetes Rev. 2010. PMID: 20034372 Review.
-
Cystic fibrosis related diabetes (CFRD)--the end stage of progressive insulin deficiency.Pediatr Pulmonol. 2011 Aug;46(8):747-60. doi: 10.1002/ppul.21495. Epub 2011 May 27. Pediatr Pulmonol. 2011. PMID: 21626717 Review.
-
[Value of continuous glucose monitoring in screening for diabetes in cystic fibrosis].Arch Pediatr. 2009 Dec;16(12):1540-6. doi: 10.1016/j.arcped.2009.09.007. Epub 2009 Oct 24. Arch Pediatr. 2009. PMID: 19854630 French.
Cited by
-
Serum kisspeptin and proopiomelanocortin in cystic fibrosis: a single study.Sci Rep. 2022 Oct 21;12(1):17669. doi: 10.1038/s41598-022-21851-8. Sci Rep. 2022. PMID: 36271282 Free PMC article.
-
Serum leptin and neuropeptide Y in patients with cystic fibrosis-A single center study.Front Med (Lausanne). 2022 Sep 14;9:959584. doi: 10.3389/fmed.2022.959584. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36186778 Free PMC article.
-
Serum levels of hormones regulating appetite in patients with cystic fibrosis - a single-center, cross-sectional study.Front Endocrinol (Lausanne). 2022 Oct 13;13:992667. doi: 10.3389/fendo.2022.992667. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 36313742 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials